drugset / Trial / NCT05839301
A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age
Phase 3
Unknown
1200 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collabJiangsu Province Centers for Disease Control and Prevention · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The goal of this clinical trial is to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.
Timeline
- Start
- 2023-04-27
- Primary completion
- 2023-07-30
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Investigational live attenuated varicella vaccine | Vaccine | 0.5 ml | Subcutaneous |